Loading...
Market
What will be the market share of Miplyffa in the Niemann-Pick disease, type C treatment market by Dec 31, 2024?
2
Resolution / Starting Odds
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Market research reports and financial analysis
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved the first oral medication to treat Niemann-Pick disease, type C (NPC). The drug, developed by Zevra Therapeutics and named Miplyffa (arimoclomol), is approved in combination with miglustat for patients aged 2 and older. This marks the first treatment to receive approval for this rare and fatal genetic disorder. The approval was announced on Friday. Zevra Therapeutics is listed under the ticker symbol ZVRA.
View original story
Similar markets
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%